Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avalyn PharmaAVLN -5.21%12 PB Ratio is 3.52 as of Sep. 18, 2026. GuruFocus rates AVLN with a GF Score™ of 12/100. Among 1,223 Biotechnology companies, Avalyn Pharma ranks worse than 59.36% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-09-18), Avalyn Pharma's share price is $31.66. Avalyn Pharma's Book Value per Share for the quarter that ended in Jun. 2026 was $8.99. Hence, Avalyn Pharma's PB Ratio of today is 3.52.
The historical rank and industry rank for Avalyn Pharma's PB Ratio or its related term are showing as below:
AVLN'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 4.05
Current: 3.52
During the past 2 years, Avalyn Pharma's highest PB Ratio was 4.05. The lowest was 0.00. And the median was 0.00.
AVLN's PB Ratio is ranked worse than 59.36% of 1223
companies
in the Biotechnology industry
Industry Median: 2.91
vs AVLN: 3.52
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Avalyn Pharma PB Ratio Related Terms
Avalyn Pharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Avalyn Pharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma PB Ratio Chart
Avalyn Pharma Annual Data
Trend
Dec24
Dec25
PB Ratio
0.00
0.00
Avalyn Pharma Quarterly Data
Mar25
Jun25
Mar26
Jun26
PB Ratio
0.00
0.00
0.00
3.66
AVLN vs LBRX, LTGO, NVAX: PB Ratio Comparison
For the Biotechnology subindustry, Avalyn Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalyn Pharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalyn Pharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Avalyn Pharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Avalyn Pharma's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Avalyn Pharma (AVLN) has a PB Ratio of 3.52 as of Sep. 18, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Avalyn Pharma and its competitors. According to the industry distribution chart, Avalyn Pharma ranks #726 out of 1223 companies in the Biotechnology industry, placing it in the top 59.4%.
Is Avalyn Pharma's PB Ratio too high?
Avalyn Pharma's current PB Ratio is 3.52. The Biotechnology industry median PB Ratio is 2.91. Avalyn Pharma's value of 3.52 is 21% above this industry median. Based on the distribution chart, Avalyn Pharma ranks #726 out of 1223 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Avalyn Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's PB Ratio compare to LBRX and LTGO?
According to the Biotechnology industry distribution chart, Avalyn Pharma ranks #726 out of 1223 companies for PB Ratio. This places Avalyn Pharma in the lower half of its industry. The industry median PB Ratio is 2.91. Avalyn Pharma's value of 3.52 is 21% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.91, based on 1,223 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avalyn Pharma's current PB Ratio of 3.52 is 21% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Avalyn Pharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avalyn Pharma's current PB Ratio is 3.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current PB Ratio of 3.52. The current PB Ratio is 3.52 and 21% above the Biotechnology industry median of 2.91. Avalyn Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current PB Ratio is 3.52 as of Sep. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
12GF Score
Get the complete analysis for AVLN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVLN has been successfully added to your 
